{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:42:03Z","timestamp":1792701723530,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T00:00:00Z","timestamp":1273622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine clinical characteristics as possible predictors of long\u2010term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients in southern Sweden with active AS starting biologic therapy for the first time between October 1999 and December 2008 (n = 243, 75% men) were included in a structured clinical followup over 2 years. Patients with clinical spondylitis had not responded to at least 2 nonsteroidal antiinflammatory drugs, whereas patients who also had peripheral arthritis (n = 121) had additionally failed at least 1 conventional disease\u2010modifying antirheumatic drug (DMARD) treatment course. The mean \u00b1 SD age at inclusion was 43 \u00b1 12 years, with a mean \u00b1 SD disease duration prior to treatment of 16 \u00b1 12 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 2\u2010year drug continuation rate was 74%. Male sex (hazard ratio [HR] of premature discontinuation 0.36 [95% confidence interval (95% CI) 0.19\u20130.68]) and the presence of peripheral arthritis (HR 0.49 [95% CI 0.27\u20130.88]) were found to be significant predictors of better drug survival. Furthermore, a trend was seen for more favorable drug continuation on treatment with etanercept as compared with infliximab (HR 0.50 [95% CI 0.25\u20131.04],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.062), whereas no differences were found comparing the 3 anti\u2013tumor necrosis factor agents in other ways. Higher baseline C\u2010reactive protein level (HR 0.99 [95% CI 0.97\u20131.00],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.12) and concomitant treatment with nonbiologic DMARDs (HR 0.61 [95% CI 0.34\u20131.10],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.10) also showed trends to entail better drug adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AS patients in this study have an excellent 2\u2010year drug survival rate of 74%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.20258","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T17:14:07Z","timestamp":1273684447000},"page":"1362-1369","source":"Crossref","is-referenced-by-count":90,"title":["Presence of peripheral arthritis and male sex predicting continuation of anti\u2013tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register"],"prefix":"10.1002","volume":"62","author":[{"given":"L. E.","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. F.","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Saxne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Geborek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_3.iii8"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_7_10_2","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long\u2010term safety and efficacy for ankylosing spondylitis (ATLAS)","volume":"35","author":"Revicki DA","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006916"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"e_1_2_7_13_2","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis JC","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_14_2","first-page":"1637","article-title":"Predictors of response to tumor necrosis factor\u2010\u03b1 blockers in ankylosing spondylitis","volume":"32","author":"Burgos\u2010Vargas R","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073098"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep422"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1941"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.011"},{"key":"e_1_2_7_20_2","first-page":"958","article-title":"Anti\u2010TNF therapy of ankylosing spondylitis in clinical practice: results from the Czech national registry ATTRA","volume":"27","author":"Pavelka K","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025130"},{"key":"e_1_2_7_22_2","first-page":"2078","article-title":"C\u2010reactive protein predicts tumor necrosis factor\u2010\u03b1 blocker retention rate in ankylosing spondylitis","volume":"34","author":"Luc M","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.9.793"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken497"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_7_26_2","unstructured":"Svensk Reumatologisk F\u00f6rening.2010. URL:http:\/\/www.svenskreumatologi.se."},{"key":"e_1_2_7_27_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_28_2","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748809098795"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20414"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31817b8789"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0877-1"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh373"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2002.17.5.669"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200401"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.7.766"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748509100407"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056937"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.01.005"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken002"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2084"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1151"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.20258","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.20258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:29:04Z","timestamp":1759422544000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.20258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,12]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/acr.20258"],"URL":"https:\/\/doi.org\/10.1002\/acr.20258","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,12]]}}}